IDH mutation and MGMT promoter methylation in glioblastoma: Results of a prospective registry

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40896-40906

  Yang, Pei ^a,b   Zhang, Wei ^a,b   Wang, Yinyan ^a,b   Peng, Xiaoxia ^a   Chen, Baoshi ^b   Qiu, Xiaoguang ^b   Li, Guilin ^a   Li, Shouwei ^c   Wu, Chenxing ^c   Yao, Kun ^c   Li, Wenbin ^d   Yan, Wei ^e   Li, Jie ^f   You, Yongping ^e   Chen, Clark C ^f   Jiang, Tao ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastomas; IDH; MGMT; Radiation; Temozolomide

Indexed keywords

ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH GENE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ADOLESCENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; REGISTER; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84951156030     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5683     Document Type: Article

References (47)

1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342:1887-92.
2. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981; 2:31-49.
3. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014; 110:551-5.
4. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008; 1:211-7.
5. Bartek J Jr, Ng K, Bartek J, Fischer W, Carter B, Chen CC. Key concepts in glioblastoma therapy. J Neurol Neurosurg Psychiatry. 2012; 83:753-60.
6. Ng K, Kim R, Kesari S, Carter B, Chen CC. Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J Neurooncol. 2012; 107:1-12.
7. Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol. 2013; 15:1114-26.
8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360:765-73.
9. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324:261-5.
10. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462:739-44.
11. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483:479-83.
12. Noushmehr H, Coetzee GA. Identification and functional annotation of GWAS risk SNPs. Cell Cycle. 2011; 10:3995-6.
13. Christensen BC, Smith AA, Zheng S, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011; 103:143-53.
14. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England journal of medicine. 2000; 343:1350-4.
15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England journal of medicine. 2005; 352:997-1003.
16. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer research. 1990; 50:6119-29.
17. Kushwaha D, Ramakrishnan V, Ng K, et al. A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget. 2014; 5:4026-39.
18. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20:2388-99.
19. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004; 4:296-307.
20. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21:5427-40.
21. Ramakrishnan V, Kushwaha D, Koay DC, et al. Post-transcriptional regulation of O( 6)-methylguanine-DNA methyltransferase MGMT in glioblastomas. Cancer Biomark. 2011; 10:185-93.
22. Herfarth KK, Brent TP, Danam RP, et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 1999; 24:90-8.
23. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13:707-15.
24. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13:916-26.
25. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10:459-66.
26. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:4150-4.
27. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. The lancet oncology. 2013; 14:e370-9.
28. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009; 10:459-66.
29. Li J, Taich ZJ, Goyal A, et al. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014; 5:7342-56.
30. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013; 81:1515-22.
31. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance. Cancer research. 2014; 74:4836-44.
32. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807-12.
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352:987-96.
34. Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. 2013; 4:1737-47.
35. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340:626-30.
36. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512:324-7.
37. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-8.
38. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014; 343:189-93.
39. Chen CC, Motegi A, Hasegawa Y, Myung K, Kolodner R, D'Andrea A. Genetic analysis of ionizing radiationinduced mutagenesis in Saccharomyces cerevisiae reveals TransLesion Synthesis (TLS) independent of PCNA K164 SUMOylation and ubiquitination. DNA repair. 2006; 5:1475-88.
40. Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomiderelated idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs. 2012; 23:1099-106.
41. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007; 114:97-109.
42. Zhang W, Zhang J, Hoadley K, et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol. 2012; 14:712-9.
43. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:1963-72.
44. Bass DM, Baylor M, Chen C, Upadhyayula U. Dansylcadaverine and cytochalasin D enhance rotavirus infection of murine L cells. Virology. 1995; 212:429-37.
45. Li J, Zhu S, Kozono D, et al. Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget. 2014; 5:882-93.
46. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl). 2007; 85:497-509.
47. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta neuropathologica. 2010; 120:707-18.